Particle size distribution testing is a critical analytical tool for understanding how pharmaceutical and biotech materials will behave during formulation, processing, delivery, and performance evaluation. From micronized APIs and inhalation powders to nanosuspensions, lipid-based systems, and reconstituted biologics, particle size profiles directly influence dissolution, content uniformity, dispersibility, sedimentation, bioavailability, manufacturability, and product consistency. BOC Sciences provides comprehensive particle size distribution testing services tailored to the material class, dosage form, and development objective of each project. Our scientists combine fit-for-purpose method selection, robust sample dispersion strategies, and application-focused data interpretation to help clients characterize complex materials with confidence, troubleshoot development bottlenecks, and make faster, better-informed decisions across pharmaceutical R&D and CMC workflows.
We use robust laser-based workflows to characterize micron- to millimeter-scale materials across APIs, intermediates, excipients, suspensions, and dry powders, integrating results with broader API analysis needs when required.
For colloidal and submicron systems, we apply dynamic light scattering workflows to assess hydrodynamic diameter, polydispersity trends, and dispersion quality in development-stage liquid formulations.
When particle shape, agglomeration, or visual heterogeneity may bias PSD interpretation, we complement measurements with orthogonal image-based assessment and broader structure characterization support.
We design customized PSD strategies for challenging pharmaceutical materials, including inhalation powders, injectable suspensions, crystalline APIs, and nanoparticle-enabled systems, supported by targeted analysis and purification expertise where necessary.
BOC Sciences helps you generate reliable particle size data that supports formulation design, process understanding, and confident technical decision-making.
Our laser diffraction workflows support broad dynamic range particle sizing for powders, granules, emulsions, and suspensions, enabling rapid and reproducible distribution profiling with configurable wet and dry sample dispersion.
For nano-scale systems, dynamic light scattering enables sensitive evaluation of hydrodynamic size and polydispersity, supporting the characterization of nanodispersions, colloids, and aggregation-prone liquid samples.
We optimize medium selection, surfactant use, sonication intensity, dilution strategy, and circulation parameters to minimize false agglomeration or dissolution-driven bias during wet particle size measurement.
Our dry dispersion capabilities are useful for cohesive and milled powders where air pressure, feed control, and deagglomeration behavior must be balanced carefully to preserve meaningful particle size profiles.
We integrate PSD results with complementary techniques such as XRD testing to distinguish particle size effects from crystallinity, phase behavior, or material transformation during processing.
Beyond raw numbers, we interpret PSD data in the context of manufacturability, dissolution behavior, suspension stability, aerosolization potential, and formulation risk to support better technical decision-making.
BOC Sciences supports particle size distribution testing for a wide range of pharmaceutical and biotech materials. Our scientists select test strategies based on sample state, dispersion behavior, intended application, and the type of development question the client needs to answer.
Share your sample type, target size range, dispersion constraints, or development question. Our team will build a fit-for-purpose particle size testing strategy aligned with your material and project goals.
We begin by reviewing material type, physical form, expected size range, dispersion behavior, formulation context, and the specific development question to determine the most suitable analytical pathway.
Our scientists select the appropriate particle sizing technique and optimize sample introduction, dispersion medium, sonication, stirring, refractive inputs, or dry feed settings to minimize artifacts and improve reproducibility.
We perform replicate testing under controlled analytical conditions, review the consistency of raw and processed data, and investigate unusual populations, multimodal behavior, or unexpected outliers when necessary.
Final deliverables include particle size distribution outputs, method details, key observations, and application-relevant interpretation to support formulation selection, process troubleshooting, or technical comparability review.
Some pharmaceutical materials rapidly agglomerate, dissolve, or change surface behavior during measurement, leading to misleading PSD results. BOC Sciences addresses this through fit-for-purpose medium selection, controlled sonication, optimized dilution design, and careful handling strategies that preserve analytical relevance while reducing measurement artifacts.
A single particle sizing technique rarely works equally well for every sample class. We help clients choose the right analytical approach for coarse powders, fine suspensions, and nano-scale systems, ensuring that the method matches the sample's physical behavior and the project's technical question rather than relying on generic measurement setups.
Particle size data becomes most valuable when it is interpreted in context. Our scientists connect PSD findings with dissolution tendency, aerosolization potential, redispersibility, milling effects, and formulation robustness, including correlation with dissolution testing or related physicochemical studies where appropriate.
Process modifications, raw material changes, or scale-up activities often alter particle populations in subtle but meaningful ways. We support comparability exercises by generating structured PSD datasets that help clients distinguish genuine material shifts from normal analytical variation and prioritize the changes most likely to affect downstream development.
Work with BOC Sciences to obtain particle size insights that are technically sound, practically useful, and tailored to your material, formulation, and development objectives.
We match the analytical technique to the sample and the decision context, helping clients avoid oversimplified methods that may produce technically correct but development-poor answers.
From wetting and deagglomeration to circulation and dilution control, we focus on the sample preparation details that often determine whether a PSD result is truly meaningful.
Particle size does not exist in isolation. We can support deeper investigation through connected services such as polymorph screening and thermal analysis when solid-state or processing effects are suspected.
Our reports are designed to help formulation scientists, project managers, and technical teams understand what the data means for next-step decisions, not just what the instrument measured.
Client Needs: A biotech startup developing mRNA therapeutics required precise characterization of Lipid Nanoparticle (LNP) carriers. They needed to ensure a highly uniform particle size to maximize encapsulation efficiency and cellular uptake.
Challenges: LNPs are highly sensitive to dilution and environmental factors. Traditional measurement techniques often suffered from particle aggregation during preparation, leading to inaccurate PDI (Polydispersity Index) readings that did not reflect the true state of the formulation.
Solution: We utilized Dynamic Light Scattering (DLS) combined with Nanoparticle Tracking Analysis (NTA) for dual-validation. By optimizing the refractive index parameters and employing a specialized low-shear dilution protocol, we captured the real-time hydrodynamic diameter. Our team performed multi-angle scattering to resolve subtle populations of aggregates that standard single-angle DLS might overlook.
Outcome: The analysis provided a comprehensive PSD profile with a PDI < 0.1, confirming a monodisperse LNP population. This data enabled the client to refine their microfluidic mixing parameters, ensuring optimal biodistribution for their clinical candidates.
Client Needs: A pharmaceutical company was developing a long-acting injectable (LAI) based on PLGA microspheres and required strict control over the release kinetics, which are directly governed by the particle size distribution.
Challenges: The microspheres exhibited a broad size range (10-150 microns). Standard sieve analysis was insufficient for high-resolution kinetic modeling, while laser diffraction required a robust dispersion method to prevent fragile microspheres from fracturing during testing.
Solution: BOC Sciences implemented Laser Diffraction (Mastersizer 3000) using a "wet dispersion" method with a customized surfactant-based dispersant. We calibrated the obscuration levels and sonication energy to ensure complete deagglomeration without compromising the structural integrity of the PLGA matrix. This allowed for the precise determination of D10, D50, and D90 values.
Outcome: By correlating PSD data with in vitro> release profiles, we identified the ideal D50 for a 30-day release cycle. The client successfully narrowed their manufacturing specifications, reducing batch-to-batch variability in drug release rates by 15%.
Client Needs: A partner required the development of a Dry Powder Inhaler (DPI) formulation where the API must fall within the "respirable range" (1-5 microns) to ensure deep lung deposition.
Challenges: Micronized powders often exhibit high surface energy, leading to significant cohesive forces and "clumping." Measuring the primary particle size versus the effective aerodynamic size in a dry state was critical but technically difficult.
Solution: We employed high-pressure dry powder dispersion laser diffraction alongside scanning electron microscopy (SEM) for morphological correlation. Our scientists optimized the air pressure (bar) in the dry feeder to overcome van der Waals forces without causing "over-milling" during the measurement process. We also performed moisture-controlled testing to evaluate the impact of humidity on particle cohesion.
Outcome: The testing suite successfully validated a micronization process that maintained 90% of particles within the 2.5 µm to 4.0 µm range. This precision was instrumental in the client achieving a high Fine Particle Fraction (FPF) during subsequent cascade impactor testing.
Particle size distribution testing is far more than a simple measurement of particle dimensions. In drug development, it can directly influence key performance attributes such as dissolution behavior, dispersion uniformity, blend consistency, suspension stability, and the reproducibility of scale-up processes. For development-stage programs, PSD data also helps teams identify formulation risks and process variability earlier, reducing trial-and-error and supporting more efficient decision-making across formulation screening, process optimization, and quality-related studies.
Common particle size distribution testing methods in drug development include laser diffraction, dynamic light scattering, microscopic image analysis, sieving, and sedimentation techniques. Different methods are suitable for different size ranges, sample forms, and research objectives. For example, nanoscale dispersed systems often require closer attention to fine particle behavior, while powders and suspensions may place greater emphasis on overall distribution width and agglomeration. Method selection should therefore be based not only on the instrument itself, but also on sample properties, dispersion conditions, and development goals.
Choosing the right particle size distribution testing strategy depends on a clear understanding of the sample’s physical properties and its intended use in development. Important considerations include whether the sample is a powder, emulsion, suspension, or nanomedicine, whether it tends to agglomerate, whether it is sensitive to shear, ultrasound, or dispersing media, and whether the project is focused on formulation screening or process investigation. A drug development service provider like BOC Sciences can align testing strategies with sample characteristics, analytical purpose, and downstream application, helping clients avoid misleading data and make more confident development decisions.
When particle size distribution data shows bimodal or multimodal patterns, unusually broad distributions, or significant batch-to-batch variation, it often suggests issues such as agglomeration, insufficient dispersion, process instability, or changes in raw material condition. These findings should not be interpreted from a single number alone. Instead, they need to be evaluated together with sample preparation procedures, testing conditions, and process context. For drug development clients, abnormal PSD data can be highly valuable because it reveals hidden development risks and helps guide formulation adjustment, milling optimization, or dispersion system improvement.
For drug development clients seeking systematic particle size distribution studies, BOC Sciences can provide integrated support from sample evaluation and method selection to data interpretation, covering a broad range of drug substances and formulation systems. We focus not only on generating test results, but also on understanding how those results relate to formulation development, process optimization, and product performance. This problem-solving, development-oriented approach helps clients turn PSD data into meaningful project decisions, while also strengthening confidence in the analytical conclusions and the overall development strategy.
What impressed us most was not just the data generation, but the way BOC Sciences helped us choose the right analytical strategy for a very challenging suspension system. Their interpretation saved our team considerable development time.
— Dr. Martin H., Formulation Scientist
Our micronized API had highly inconsistent particle size results across internal tests. BOC Sciences quickly identified the dispersion issue and delivered a much more reliable workflow for our project team.
— Claire T., CMC Project Manager
The combination of PSD analysis with supporting material characterization made the conclusions far more useful than a standard sizing report. Their scientists clearly understood the broader development context.
— Dr. James W., Solid State Development Lead
We needed actionable data, not just instrument output. BOC Sciences provided a well-structured report that helped our formulation and analytical teams align quickly on the next experiments.
— Elena R., Senior Analytical Manager
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
